METHOD OF TREATING PROSTATE CANCER WITH GONADOTROPHIN RELEASING HORMONE (GnRH) ANTAGONIST DEGARELIX

摘要

The invention provides methods for the treatment of prostate cancer in a subject identified as being at risk for or having an increased likelihood of developing a cardiovascular disease before the treatment, comprising administering to said subject degarelix at an initial dose of 160 to 320 mg and at a maintenance dose of 60 to 160 mg, once every 20 to 36 days thereafter.